CORE THERAPY
ActiveSummary
CORE THERAPY is younger than twelve months; there is no public track record yet to compute a bankruptcy probability from. The 2025 annual accounts show negative equity (€-7k) and a net result of €-7k. Its solvency ranks better than 15% of 14128 sector peers (fiscal year 2025). The company has been active since 2025 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Score 2025
Axes
Profitability22
Solvency19
Growth-
Track record50
Credit verdict
No credit on open account
Liquidity ample (current ratio 2.48; short-term debt: 21.1% and cash: 26.6% of total assets), but equity is negative.
Credit check for your own amount and term
Open the credit simulator : see how the verdict changes with amount, term and advance.
Signals
Three signals. The signal on the left, the evidence on the right.
+raises risk○neutral
raises risk · Young company
Founded in 2025, under 3 years in business. Failure risk is statistically highest between 2 and 8 years after founding.
KBO · incorporation dateAge against the risk zone
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 28-08-2026, 28 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 1 filingDeviation from the deadline
2025
28 d late
← before the deadline
after the deadline →
Checked, nothing found (1)
History
Go further with this company
How much credit can you give this customer, and on what term?Credit simulator What should you check before you do business with this company?Supplier due diligence Accepting this client? The AML file with identity, beneficial owners and sanctions lists.AML client file How does this company compare with its sector?Sector benchmark Roughly what is this company worth?Value indication What held for this company on a given day: board, seat, name?Company as of a date
Financials · fiscal year 2025, micro schema
Equity
€-7k
Total assets
€122k
Net result
€-7k
Working capital
€38k
Turnover and EBIT margin not published: the micro schema does not require them.
Balance-sheet composition
Assets €122k
Fixed assets
€58k
Current assets
€64k
Key figures and ratios
Solvency
-5.6%
Current ratio
2.48
Debt to equity
-18.82
ROA
-6.0%
Debt
€129k
Debt ≤ 1 year
€26k
Debt > 1 year
€103k
Annual accounts
| Line | 2025 |
|---|---|
| Gross operating margin9900 | €-7k |
| Operating profit (loss)9901 | €-7k |
| Financial charges65/66B | €608 |
| Recurring financial charges65 | €608 |
| Profit (loss) for the period before taxes9903 | €-7k |
| Profit (loss) for the period9904 | €-7k |
| Profit (loss) for the period to be appropriated9905 | €-7k |
| Line | 2025 | |
|---|---|---|
| Assets | ||
| Total assets20/58 | €122k | |
| Fixed assets21/28 | €58k | |
| Tangible fixed assets22/27 | €58k | |
| Assets under construction and advance payments27 | €58k | |
| Current assets29/58 | €64k | |
| Amounts receivable within one year40/41 | €31k | |
| Trade receivables40 | €30k | |
| Other amounts receivable41 | €2k | |
| Cash at bank and in hand54/58 | €32k | |
| Deferred charges and accrued income490/1 | €224 | |
| Equity and liabilities | ||
| Total equity and liabilities10/49 | €122k | |
| Equity10/15 | €-7k | |
| Contributions10/11 | €500 | |
| Profit (loss) carried forward14 | €-7k | |
| Amounts payable17/49 | €129k | |
| Amounts payable after more than one year17 | €103k | |
| Financial debts170/4 | €103k | |
| Amounts payable within one year42/48 | €26k | |
| Current portion of amounts payable after more than one year42 | €8k | |
| Trade debts44 | €555 | |
| Suppliers440/4 | €555 | |
| Other amounts payable47/48 | €18k | |
| Accrued charges and deferred income492/3 | €230 | |
| Line | 2025 |
|---|---|
| Profit (loss) for the period9904 | €-7k |
| Operating cash flow (approximation) | €-7k |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
2026
28-08
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema · 28 days late
NBB filing
0 of 1 act read
About the unread acts
We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Lasne · 1 establishment unit since 2025
Ground area
3,127 m²
Building footprint
466 m²
Parcel 25076A0608/00B000, Wallonia. Linked by address, not a title deed.
13
companies at this address
See who is registered here
1 establishment unit
CORE THERAPY
since 20252.379.883.815
1 parcel
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 25076A0608/00B000 | Wallonia | 3,127 m² | 1 · 466 m² | - |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector and region
Boneff
BE 0419.195.990
Lasne
CAPSULE IMMO
BE 1016.648.090
Lasne
CASTOR - IMMO
BE 0447.419.428
Lasne
CORPORENT
BE 0750.714.078
Lasne
Davolimmo
BE 0599.811.475
Lasne
This company's figures show no positive equity and no headcount, so a size comparison is not possible. These companies share only the sector and the region. Of 12,041 companies in sector 68203 we hold annual accounts for 5,994. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded10-10-2025
Fiscal year end31-12
Activities, NACEBEL 2025
68203Renting and operating of own or leased non-residential real estate, excluding land
Scores and ratios are computed by Checked and are not a credit decision.